Immune Checkpoint Inhibitor Toxicity in 2018

Douglas B. Johnson; Sunandana Chandra; Jeffrey A. Sosman

doi:10.1001/jama.2018.13995

Immune Checkpoint Inhibitor Toxicity in 2018

Douglas B. Johnson, Sunandana Chandra, Jeffrey A. Sosman^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Short survey › peer-review

91 Scopus citations

Original language	English (US)
Pages (from-to)	1702-1703
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	320
Issue number	16
DOIs	https://doi.org/10.1001/jama.2018.13995
State	Published - Oct 23 2018

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1001/jama.2018.13995

Cite this

@article{81e123584f964cd49c8cefa7a8dae19f,

title = "Immune Checkpoint Inhibitor Toxicity in 2018",

author = "Johnson, {Douglas B.} and Sunandana Chandra and Sosman, {Jeffrey A.}",

note = "Funding Information: Funding/Support: Dr Johnson is funded by Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Johnson serves on advisory boards for Array Biopharma, Bristol-Myers Squibb, Incyte, Merck, Novartis, and Navigate BP, and receives research funding from Bristol-Myers Squibb and Incyte. Dr Chandra receives consulting fees as an advisory board member for Bristol-Myers Squibb, EMD Serono, Regeneron, and Novartis, and as a speaker{\textquoteright}s bureau member from Array Biopharma. Dr Sosman serves on advisory boards for Array Biopharma, Bristol-Myers Squibb, and Genentech and receives research funding from Merck.",

year = "2018",

month = oct,

day = "23",

doi = "10.1001/jama.2018.13995",

language = "English (US)",

volume = "320",

pages = "1702--1703",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "16",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitor Toxicity in 2018

AU - Johnson, Douglas B.

AU - Chandra, Sunandana

AU - Sosman, Jeffrey A.

N1 - Funding Information: Funding/Support: Dr Johnson is funded by Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Johnson serves on advisory boards for Array Biopharma, Bristol-Myers Squibb, Incyte, Merck, Novartis, and Navigate BP, and receives research funding from Bristol-Myers Squibb and Incyte. Dr Chandra receives consulting fees as an advisory board member for Bristol-Myers Squibb, EMD Serono, Regeneron, and Novartis, and as a speaker’s bureau member from Array Biopharma. Dr Sosman serves on advisory boards for Array Biopharma, Bristol-Myers Squibb, and Genentech and receives research funding from Merck.

PY - 2018/10/23

Y1 - 2018/10/23

UR - http://www.scopus.com/inward/record.url?scp=85054515309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054515309&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.13995

DO - 10.1001/jama.2018.13995

M3 - Short survey

C2 - 30286224

AN - SCOPUS:85054515309

VL - 320

SP - 1702

EP - 1703

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 16

ER -

Immune Checkpoint Inhibitor Toxicity in 2018

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this